TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12478901
Drug: rhIL-11 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (50 micrograms/kg/d) administered subcutaneously for 14 consecutive days after chemotherapy
Study: 1600052
Drug: Lansoprazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (all doses)
Study: 2122719
Drug: Lactase-containing tablets
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase-containing tablets
Study: 30377198
Drug: Epacadostat (IDO1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat (IDO1-selective inhibitor) in combination with pembrolizumab
Study: 21276122
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of lycopene for 12 weeks
Study: 19738090
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) algorithm for antibiotic administration
Study: 15499533
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) at 6.4 mg/kg DHA
Study: 15499533
Drug: Dihydroartemisinin-piperaquine plus
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine plus additional artemisinin derivative (DP+) at 12 mg/kg
Study: 2971549
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean final daily dose: 13.1 mg)
Study: 24929949
Drug: fosamprenavir/ritonavir 700/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosamprenavir/ritonavir 700/100 mg b.i.d. for 16 days with a single dose of olanzapine 15 mg on Day 13
Study: 24929949
Drug: olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine 10 mg alone
Study: 12442349
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg via 15 min infusion every 3-4 weeks)
Study: 12442349
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg via 2 hr infusion)
Study: 10456490
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 ml orange juice)
Study: 445503
Drug: Cyclophosphamide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide alone (1 g/m2)
Study: 445503
Drug: Cyclophosphamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (500 mg/m2) plus Adriamycin (40 mg/m2)
Study: 445503
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (Cyclophosphamide plus Adriamycin)
Study: 30202898
Drug: Sequential Monte
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Monte-G HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Monte Carlo adaptation for updating posterior distribution
Study: 31109746
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after SF aspiration
Study: 29878718
Drug: Double diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double diluted abobotulinum toxin type A (Dysport) (dilution of 15 mL to give 3.33 units per 0.1 mL)
Study: 29878718
Drug: Common concentration
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common concentration of abobotulinum toxin type A (Dysport) (dilution of 7.5 mL to give 6.67 units per 0.1 mL)
Study: 17587751
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg once daily
Study: 17083180
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment (8 modes)
Study: 8796182
Drug: High-dose FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FSH (150 IU)
Study: 8796182
Drug: Low-dose FSH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FSH
Study: 1643014
Drug: Conventional-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional-dose cytarabine (200 mg/m2/d by continuous infusion)
Study: 1643014
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine (500 mg/m2 every 12 h)
Study: 29326183
Drug: Laparoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic treatment (control)
Study: 18351298
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (only instructed to instil bimatoprost daily)
Study: 18351298
Drug: Bimatoprost therapy
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost therapy
Study: 10384851
Drug: Naseptin antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naseptin antiseptic nasal carrier cream alone (Group A)
Study: 10384851
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Naseptin cream and silver nitrate cautery (Group B)
Study: 10384851
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of age groups in both treatment arms
Study: 2050827
Drug: Procainamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (750 mg IV) with probenecid (2 g orally)
Study: 2050827
Drug: Procainamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (750 mg IV) without probenecid
Study: 31781762
Drug: Ganciclovir preemptive
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir preemptive therapy
Study: 30962677
Drug: Aprocitentan 100
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 100 mg once a day (qd)
Study: 30962677
Drug: Aprocitentan 25
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 25 mg and above
Study: 30962677
Drug: Aprocitentan up
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan up to 10 µg/mL
Study: 30962677
Drug: Aprocitentan (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan (single and multiple doses)
Study: 30962677
Drug: Aprocitentan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan (100 mg qd)
Study: 25624076
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.3mg/kg)
Study: 25624076
Drug: Morphine (0.1mg/kg)
Normalized name: morphine 0.23 MG
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (0.1mg/kg)
Study: 23266359
Drug: 8mg fesoterodine
Normalized name: fesoterodine fumarate 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg fesoterodine tablet formulation (test)
Study: 23266359
Drug: 8mg fesoterodine
Normalized name: fesoterodine fumarate 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg fesoterodine tablet formulation (reference)
Study: 15472806
Drug: Anidulafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (100 mg on day 1, followed by 50 mg per day)
Study: 15472806
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg on day 1, followed by 100 mg per day)
Study: 8489556
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A (doses > or = 0.5 mg)
Study: 8489556
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A (multiple doses)
Study: 8489556
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A (single oral dose)
Study: 28074483
Drug: Randomisation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomisation to opposite treatment groups
Study: 17205304
Drug: Drinking solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking solution (formulation 1)
Study: 17205304
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation 2B
Study: 17205304
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation 2C
Study: 9832300
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg single dose
Study: 8607318
Drug: Thiopentone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 5.0 mg/kg
Study: 8607318
Drug: Thiopentone 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 6.0 mg/kg
Study: 2693440
Drug: Gugulipid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gugulipid (500 mg tds for 12 weeks after 8 weeks of diet and placebo)
Study: 28260223
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of solifenacin 5‐mg tablets and pregabalin 75‐mg capsules bid (Group A)
Study: 28260223
Drug: Solifenacin 5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5‐mg tablets (Group B)
Study: 28260223
Drug: Pregabalin 75‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75‐mg capsules bid (Group C)
Study: 17509580
Drug: Estro-progestin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estro-progestin treatment (2 mg of hemihydrate E(2) and 10 mg of dydrogesterone in a continuous sequential regimen)
Study: 12768153
Drug: Oxiplex/SP Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex/SP Gel (1-3 mL)
Study: 10681072
Drug: Mibefradil (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (50-100 mg)
Study: 9501335
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (0.15-0.17 mg/m3)
Study: 9501335
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (0.03-0.08 mg/m3)
Study: 9501335
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (0.02-0.03 mg/m3)
Study: 1439620
Drug: Arthrotec (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrotec (50 mg diclofenac and 200 micrograms misoprostol)
Study: 1439620
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac (control)
Study: 1439620
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Arthrotec and diclofenac)
Study: 30024627
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A soft capsules for 7 days
Study: 30024627
Drug: Conventional anti‐inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti‐inflammatory therapy and aerosol inhalation
Study: 26162646
Drug: Daikenchuto (15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (15.0 g/day, 5 g three times a day)
Study: 23323673
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g kg(‐1) body mass sodium bicarbonate (NaHCO3)
Study: 23323673
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g kg(‐1) body mass sodium chloride (placebo)
Study: 17468868
Drug: Fondaparinux 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 0.75 mg
Study: 17468868
Drug: Fondaparinux 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 1.5 mg
Study: 17468868
Drug: Fondaparinux 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 3.0 mg
Study: 14535871
Drug: 13C‐methacetin breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C‐methacetin breath test (75 mg per os)
Study: 11085191
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg/kg/d of ZnSO4)
Study: 3325260
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg, twice daily for a mean duration of 8.77 days
Study: 3325260
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg, twice daily for a mean duration of 8.77 days
Study: 3325260
Drug: Ofloxacin 800
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin 800 mg, twice daily for a mean duration of 8.77 days
Study: 29444690
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg NBMI
Study: 29444690
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg NBMI
Study: 24445732
Drug: 6-monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-monthly follow-up with the SFP program (group A)
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 0.32 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 0.56 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 0.75 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 1.0 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 1.8 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 2.4 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 3.2 g/70 kg
Study: 20526195
Drug: GHB at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB at doses of 0.32-3.2 g/70 kg
Study: 18427285
Drug: Tetradecylthioacetic acid
Normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetradecylthioacetic acid (TTA) 200 mg
Study: 18427285
Drug: Tetradecylthioacetic acid
Normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetradecylthioacetic acid (TTA) 600 mg
Study: 18427285
Drug: Tetradecylthioacetic acid
Normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetradecylthioacetic acid (TTA) 1000 mg
Study: 12826549
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.1 mg (Group I)
Study: 18575162
Drug: Psoas compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II)
Study: 12826549
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (Group I)
Study: 7578986
Drug: GM-CSF mouthwash
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF mouthwash (0.01, 0.1, 1.0 or 10 mcg/ml)
Study: 7578986
Drug: GM-CSF mouthwash
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF mouthwash (various doses)
Study: 2197002
Drug: Propofol 6
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6 mg.kg‐1.hr‐1 and nitrous oxide 50% in oxygen
Study: 2197002
Drug: Propofol 9
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 9 mg.kg‐1.hr‐1 with 100% oxygen
Study: 2197002
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg.kg‐1 and nitrous oxide 50% in oxygen with enflurane 1%
Study: 21790620
Drug: Self-help book
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help book (cognitive behavioral therapy for insomnia)
Study: 15319567
Drug: Average QOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average QOL during treatment
Study: 9286887
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg rectal acetaminophen
Study: 9286887
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg rectal acetaminophen
Study: 9286887
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg rectal acetaminophen
Study: 9286887
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose of 10-15 mg/kg rectal acetaminophen
Study: 9286887
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose recommendation
Study: 3549010
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg single oral dose of ciprofloxacin
Study: 3549010
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg single oral dose of ciprofloxacin
Study: 22289549
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day rosuvastatin
Study: 23523089
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (RT and Tamoxifen)
Study: 20434199
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS), 200 microg once daily
Study: 18836092
Drug: Multifactorial strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial strategy of pain management (n = 107) including anesthesic patch, specified vaccines, child education, parental accompaniment, and distraction with soap bubbles
Study: 10695097
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg nimesulide beta cyclodextrin
Study: 10695097
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nimesulide
Study: 22480204
Drug: UP446 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP446 250 mg/day
Study: 22480204
Drug: UP446 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP446 500 mg/day
Study: 22480204
Drug: Placebo (CMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (CMC capsule)
Study: 21084042
Drug: FPNS 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPNS 200 µg
Study: 21084042
Drug: FPNS (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPNS (100, 200, 400, and 800 µg)
Study: 22064877
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (mean, 12.7 mg/L)
Study: 22064877
Drug: Low-iron formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron formula (mean, 2.3 mg/L)
Study: 19818062
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride ER 60 mg
Study: 14754497
Drug: Albendazole for
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole for 7 days (400 mg/day)
Study: 14754497
Drug: Albendazole for
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole for 5 days (400 mg/day)
Study: 14754497
Drug: Albendazole for
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole for 3 days (400 mg/day)
Study: 11509075
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for the affected side (1 hour, 3 times a week for 6 weeks) combined with mental practice (listening to an audiotape 2 times a week, plus additional home practice)
Study: 8425995
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal nitroglycerin
Study: 8945675
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal nitroglycerin
Study: 3434740
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine 600 micrograms
Study: 28131632
Drug: CD56-enriched donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD56-enriched donor cell infusion after post-transplantation cyclophosphamide (PTCy)
Study: 28131632
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 patients without CD56-enriched donor cell infusion)
Study: 28131632
Drug: CD56-enriched donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD56-enriched donor cell infusion after PTCy
Study: 25373391
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg once a day
Study: 25373391
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg once a day
Study: 23406489
Drug: 1 Day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Day Acuvue Moist for Astigmatism (daily disposable toric soft lens)
Study: 23406489
Drug: Acuvue Oasys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuvue Oasys for Astigmatism (2-weekly replacement, re-usable toric soft lens)
Study: 11124758
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g D‐tagatose added to the diet daily
Study: 7942652
Drug: Carbamide peroxide
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamide peroxide home bleaching agent for 72 hours before bonding
Study: 31223042
Drug: 19.5 mg
Normalized name: camphor 19.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19.5 mg LNG-IUS
Study: 18490865
Drug: Methyl-cellulose placebo
Normalized name: Methyl cellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl-cellulose placebo gel
Study: 30670043
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no alert for tobacco treatment.
Study: 18720937
Drug: Somatostatin 6
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 6 mg/day infused separately